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Vitamin D has endocrine function as a key regulator of calcium absorption and bone homeostasis and also has
intracrine function as an immunomodulator. Vitamin D deﬁciency before hematopoietic stem cell trans-
plantation (HSCT) has been variably associated with higher risks of graft-versus-host disease (GVHD) and
mortality. Children are at particular risk of growth impairment and bony abnormalities in the face of pro-
longed deﬁciency. There are few longitudinal studies of vitamin D deﬁcient children receiving HSCT, and the
prevalence and consequences of vitamin D deﬁciency 100 days after transplant has been poorly studied.
Serum samples from 134 consecutive HSCT patients prospectively enrolled into an HSCT sample repository
were tested for 25-hydroxy (25 OH) vitamin D levels before starting HSCT (baseline) and at 100 days after
transplantation. Ninety-four of 134 patients (70%) had a vitamin D level < 30 ng/mL before HSCT, despite
supplemental therapy in 16% of subjects. Post-transplant samples were available in 129 patients who survived
to day 100 post-transplant. Vitamin D deﬁciency persisted in 66 of 87 patients (76%) who were already
deﬁcient before HSCT. Moreover, 24 patients with normal vitamin D levels before HSCT were vitamin D
deﬁcient by day 100. Overall, 68% of patients were vitamin D deﬁcient (<30 ng/mL) at day 100, and one third
of these cases had severe vitamin D deﬁciency (<20 ng/mL). Low vitamin D levels before HSCT were not
associated with subsequent acute or chronic GVHD, contrary to some prior reports. However, severe vitamin
D deﬁciency (<20 ng/mL) at 100 days post-HSCT was associated with decreased overall survival after
transplantation (P ¼ .044, 1-year rate of overall survival: 70% versus 84.1%). We conclude that all pediatric
transplant recipients should be screened for vitamin D deﬁciency before HSCT and at day 100 post-transplant
and that aggressive supplementation is needed to maintain sufﬁcient levels.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION together with widened epiphyseal plates at the end of long
Vitamin D has important endocrine functions, such as
modifying absorption of dietary calcium and regulating bone
homeostasis. Severe dietary vitamin D deﬁciency manifests
as rickets in children. In children, the bone matrix is poorly
mineralized, and abnormal chondrocyte maturation leads to
the classical bowing of the legs described in rachitic children,dgments on page 1631.
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ty for Blood and Marrow Transplantation.bones and costochondral junctions, frontal bossing of the
skull, and delayed tooth eruption [1]. In contrast, adults have
sufﬁcient mineral in the long bones and epiphyseal plates are
closed, so there are no visible skeletal abnormalities but
rather manifestations of osteomalacia. The unmineralized
matrix beneath the periosteal membrane, which is heavily
innervated with sensory ﬁbers, is hydrated and pushed up-
ward, often causing throbbing, aching bone pain. These data
support possible important differences in clinical manifes-
tations of vitamin D deﬁciency between children and adults.
Studies have indicated widespread vitamin D deﬁciency
or insufﬁciency in the US population, perhaps because of
inadequate dietary intake, sedentary lifestyles, and reduced
Table 1
Patient (N ¼ 134) and Transplant Demographics
Characteristic Value
Male/female 87/47
Mean age, yr (range) 7.1 (2.7-14.9)
Diagnosis
Bone marrow failure 36 (27%)
Immune deﬁciency 52 (38.8%)
Malignancy 38 (28.2%)
Genetic/metabolic 8 (6%)
Race
White 116 (86.6%)
Nonwhite 18 (13.4%)
Conditioning regimen
Myeloablative 73 (54.4%)
Reduced intensity 61 (45.5%)
Donor type
Related 40 (29.8%)
Unrelated 94 (70.2%)
Stem cell source
Bone marrow 108 (80.6%)
PBSC 16 (11.9%)
Cord blood 10 (7.5%)
HLA matching
8/8 Allele matched 108 (80.6%)
Mismatched 26 (19.4%)
PBSC indicates peripheral blood stem cell.
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clinically signiﬁcant vitamin D deﬁciency is complicated by
changing views on optimal vitamin D levels. There is broad
agreement that levels less than 20 ng/mL indicate deﬁciency,
and many consider levels below 30 ng/mL insufﬁcient [1,3,4].
However, some other authors argue that levels above 50 or
75 ng/mL are optimal, based at least in part on the serum
vitamin D level above which no further suppression of
parathyroid hormone occurs [2,4,5].
Vitamin D is stored in the body as 25-(OH)-vitamin D, an
inactive form that is activated enzymatically to 1,25 (OH)
vitamin D in the kidneys, an activity that is impaired in sig-
niﬁcant renal dysfunction. The same enzyme (25-hydroxy-
vitamin D-1-hydroxylase) activity that activates vitamin D in
the kidney is present in other tissues, including breast,
prostate, brain, activated T cells, and antigen-presenting cells
such as activated macrophages. The binding of 1,25 (OH)
vitamin D to the nuclear vitamin D receptor in macrophages,
dendritic cells, and T cells increases expression of cath-
elicidin, promoting innate immune responses and destruc-
tion of infective agents [6,7]. There is also likely secretion of
1,25 (OH) vitamin D, acting locally on T and B lymphocytes.
Vitamin D receptor stimulation leads to modiﬁcation of
cytokine secretion, through direct interactionwith vitamin D
responsive promoter elements and perhaps indirectly
through interaction with other transcription factors [8].
These data support potential important effects of vitamin D
deﬁciency on immune recovery and perhaps on graft-
versus-host disease (GVHD) after hematopoietic stem cell
transplantation (HSCT).
Previous studies of vitamin D deﬁciency after HSCT have
produced conﬂicting results, with some indicating reduced
survival and increased risk of acute or chronic GVHD and
some ﬁnding no impact on some or all of these endpoints.
Few studies have studied vitamin D levels patients longitu-
dinally, and most studies examined adults and not children.
Our center focuses on children with genetic disorders who
generally have not had prior chemotherapy, so we hypoth-
esized that the frequency of vitamin D deﬁciency might be
lower in our patient population. Moreover, approximately
half of our children receive reduced-intensity conditioning
regimens that we hypothesized would be less likely to be
associated with vitamin D deﬁciency. In contrast to these
hypotheses, we found a very high frequency of vitamin D
deﬁciency before transplant and found that many children
remain or become vitamin D deﬁcient during the ﬁrst 100
days after transplant.METHODS
Patients and Transplant Procedures
Patient and transplant characteristics are summarized in Table 1. Chil-
dren in this study were enrolled in 1 of 2 prospective cohort studies, the ﬁrst
a biomarkers study for thrombotic microangiopathy and the second the
Cincinnati Children’s Hospital and Medical Center BMT repository. All
consecutive participants in these 2 studies were eligible to participate and
had signed consent for sample collection for biological studies of compli-
cations of transplantation. The institutional review board of Cincinnati
Children’s Hospital Medical Center approved the study.
Median patient age was 7.1 years, and most patients were transplanted
for a nonmalignant disease. Most recipients were white, and almost half
received a reduced-intensity preparative regimen. Most donors were un-
related adult donors, and most grafts were bone marrow. Clinical data were
abstracted from the transplant database and veriﬁed by chart review if
needed. Registered dieticians with experience in HSCT oversaw dietary is-
sues in all children, but routine measurements of vitamin D were not made
without clinical indications. If a clinical indication arose and vitamin D
deﬁciency or insufﬁciency were identiﬁed, supplementation with recom-
mended daily doses were prescribed.Dietary Management and Supportive Care during HSCT
A registered dietician assessed and followed all patients undergoing
HSCT. Patients were allowed to eat normally while following the dietary
restrictions of the low bacteria diet. If unable to consume adequate cal-
ories, patients were started on enteral feeding using an age-appropriate
formula. Parenteral nutrition was provided to children unable to
tolerate enteral nutrition. Vitamin and mineral supplementation were
provided on an as-needed basis. Antifungal prophylaxis was primarily
voriconazole, with pharmacogenetically assigned drug dosing, adjusted
pharmacokinetically to maintain therapeutic levels. Children with
contraindication or intolerance to voriconazole were treated with
micafungin.Vitamin D Analysis by Ultra-High-Performance Liquid Chromatography
Coupled to Electrospray Tandem Mass Spectrometry
Serum samples were collected prospectively on consenting HSCT re-
cipients less than 18 years old receiving their ﬁrst HSCT, and samples were
stored at 80C until analyzed. Human serum concentrations of vitamin D
(vitamin D2 and D3) and 25-hydroxyvitamin D (25-OH D2 and 25-OH-D3)
were determined by ultra-high-performance liquid chromatography
coupled to electrospray tandem mass spectrometry (Waters, Milford, MA)
[9]. Serum samples were extracted by liquideliquid extraction with methyl
tert-butyl ether/ethyl acetate/hexane (5:4:1). Combined extracts were dried
and derived by 4-phenyl-1,2,4-thriazoline-3,5-dione before transfer to
sample vials. Quantiﬁcation was conducted with multiple reaction moni-
toring and with a stable isotope dilution ultra-high-performance liquid
chromatography coupled to electrospray tandem mass spectrometry
method on a Supelcosil LC-18-DB column (33  3 mm, 3 mm; Sigma, St.
Louis, MO). A vitamin D level < 30 ng/mL was deﬁned as vitamin D insuf-
ﬁciency, and a vitamin D level < 20 ng/mL was deﬁned as vitamin D
deﬁciency.Statistical Analysis
Continuous and categorical variables were compared using Wilcoxon
rank sum test and Fisher’s exact test, respectively. Survival and cumu-
lative incidence curves, percentages, and standard errors were computed
using the Kaplan-Meier method. Survival between groups was assessed
using log rank tests. For other time to event data, Gray’s method for
competing risks was used. Death and relapse (for GVHD) were treated as
competing risks. Cox proportional hazards was used for the multivariable
survival models. A backward selection model was used, including all
variables mentioned in the demographic table, but only signiﬁcant vari-
ables were retained in the ﬁnal model. All statistical computations were
performed using R software (version 3.0.1; www.r-project.org). Statistical
signiﬁcance was determined at the .05 level.
Table 2
Vitamin D Levels before HSCT
Vitamin D
Insufﬁciency
(<30 ng/mL)
Vitamin D
Deﬁciency
(<20 ng/mL)
All patients (N ¼ 134) 70% (94/134) 33% (45/134)
Patients on vitamin D
supplementation (n ¼ 28)
46% (13/28) 18% (5/28)
Patients not on vitamin D
supplementation (n ¼ 106)
76% (81/106) 38% (40/106)
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Vitamin D Deﬁciency
Seventy percent of children (94/134) were vitamin D
insufﬁcient (<30 ng/mL) and 33% (45/134) were vitamin D
deﬁcient (<20 ng/mL) before start of transplant (Table 2).
There was no signiﬁcant difference in mean vitamin D level
according to latitude of residence (P ¼ 1.0) or cystatin
Ceestimated glomerular ﬁltration rate. Median cystatin
Ceestimated glomerular ﬁltration rate was 99.9 mL/min/1.73
m2 (range, 90.6 to 109.5) in those with vitamin D> 20 ng/mL
before HSCT and was 100.6 mL/min/1.73 m2 (range, 88.5 to
117.2) in thosewith vitamin D< 20 ng/mL (P¼ .54). Similarly,
median cystatin Ceestimated glomerular ﬁltration rate was
80.0 mL/min/1.73 m2 (range, 64.7 to 91.3) in those with
vitamin D > 20 ng/mL 100 days post-HSCT and was 73.9 mL/
min/1.73 m2 (range, 63.8 to 91) in those with vitamin D < 20
ng/mL (P ¼ .52). Moreover, vitamin D deﬁciency was not
more frequent in nonwhite children (P ¼ .3), although the
number of nonwhite childrenwas small (n¼ 18), limiting the
ability to see all but a large difference. Some seasonal dif-
ference was seen, with 50% of children transplanted in the
winter quarter having a pre-HSCT vitamin D level less than
20 ng/mL compared with 13% transplanted in spring, 33% in
summer, and 37% in fall (P ¼ .025). Twenty-eight children
(21%) were receiving vitamin D supplements before trans-
plant; despite this, 13 of these children (46%) were vitamin D
insufﬁcient (30 ng/mL) and 5 had severe vitamin D deﬁ-
ciency (20 ng/mL).
At day 100, 68% of children (88/129) were vitamin
D insufﬁcient (<30 ng/mL) and 31% vitamin D deﬁcient
(<20 ng/mL) (Table 3). Twenty-nine children (21%) were
receiving vitamin D at day 100; despite this, 11 of these
children (38%) were still vitamin D insufﬁcient (30 ng/mL)
and 11 had severe vitamin D deﬁciency (20 ng/mL).
Seventy-six percent of children who were already deﬁcient
at baseline remained deﬁcient or insufﬁcient until 100 days.
Fifty-seven percent of childrenwith normal vitamin D levels
before transplant-developed deﬁciency or insufﬁciency by
100 days after transplantation.Table 3
Vitamin D Levels at Day 100
Vitamin D
Insufﬁciency
(<30 ng/mL)
Vitamin D
Deﬁciency
(<20 ng/mL)
All patients (N ¼ 129) 68% (88/129) 31% (40/129)
Patients on vitamin D
supplementation (n ¼ 29)
38% (11/29) 38% (11/29)
Patients not on vitamin D
supplementation (n ¼ 100)
77% (77/100) 29% (29/100)Engraftment and Acute and Chronic GVHD
No differences were detected in time to engraftment
between vitamin D insufﬁcient and deﬁcient children and
children with adequate vitamin D measured before HSCT.
The cumulative incidence of acute GVHD was similar in
children with vitamin D insufﬁciency and those without
(P ¼ .49, 100-day acute GVHD incidence 32% versus 40%) and
in children with vitamin D deﬁciency and those without
(P ¼ .73, 100-day acute GVHD incidence 33% versus 35%),
measured before HSCT. Similarly, the cumulative incidence of
chronic GVHD was similar in children with vitamin D insuf-
ﬁciency and those without (P ¼ .24, 1-year cGVHD incidence
4% versus 7%) and in children with vitamin D deﬁciency
and those without (P ¼ .86, 1-year cGVHD incidence 3%
versus 13%), measured before HSCT.
Survival
Overall survival was similar in children with vitamin D
insufﬁciency at baseline and those without (78% versus 75%,
P¼ .65) and in childrenwith vitamin D deﬁciency at baseline
and those without (75% versus 78%, P ¼ .54). There was no
difference in survival between childrenwith vitamin D levels
above and below 30 ng/mL at day 100 (vitamin D insufﬁ-
ciency; 78% versus 83%, P ¼ .77). In contrast, survival was
signiﬁcantly reduced in children with severe vitamin D
deﬁciency (20 ng/mL) at day 100 (Figure 1). A multivariable
model, adjusting survival for occurrence of GVHD, showed an
increased mortality associated with GVHD (odds ratio, 2.67;
P < .01) and a nonstatistically signiﬁcant reduction in mor-
tality in children with a vitamin D level > 20 ng/mL (odds
ratio, .56; P ¼ .11), raising the possibility that increased
mortality associatedwith vitamin D deﬁciencymay be due in
part to an association of vitamin D deﬁciency with GVHD and
steroid use.
Infections
The frequency of viral infections was not increased in
children with vitamin D levels above and below 20 ng/mL
before HSCT (42/89 [47%] versus 23/45 [51%], P ¼ .36). In
addition, the frequency of bacterial infections was similar in
those with vitamin D levels above and below 20 ng/mL
before HSCT (20/89 [22%] versus 9/45 [20%], P ¼ 1.0).
Examination of causes of death showed no difference in the
number of deaths from sepsis among children with vitamin
D levels below and above 20 ng/mL at day 100 (5/40 versus
9/88, not signiﬁcant).
DISCUSSION
This study reports the frequency and impact of vitamin D
deﬁciency in a cohort of children receiving transplant mostly
for nonmalignant diagnoses. The data show a high frequency
of vitamin D deﬁciency. Importantly, some vitamin
Desufﬁcient children become vitamin D deﬁcient in the ﬁrst
100 days after transplant, and those who were vitamin D
deﬁcient before transplant in general remained insufﬁcient,
despite supervision by a registered dietician supplying rec-
ommended supplementation, suggesting that higher doses
of supplements may be needed for this population. Our data
also showed an association between very low (<20 ng/mL)
levels of vitamin D and reduced survival. The signiﬁcance of
this difference was lost after adjustment for GVHD, and we
propose that the effect of vitamin D deﬁciency on survival
may be indirect and a consequence of GVHD rather than
vitamin D deﬁciency per se.
Figure 1. Overall survival after HSCT in children with a day 100 vitamin D
level < 30 ng/mL (A) and <20 ng/mL (B).
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ﬁcient or deﬁcient before the start of transplant. These data
should be considered in the light of reports of frequent low
vitamin D levels in healthy US children. Weng et al. [2]
measured 25(OH) vitamin D levels in 382 normal children
ages 6 to 21 in the United States and found a median con-
centration of 28 ng/mL, with 55% of subjects having levels
below 30 ng/mL. We found levels below 30 ng/mL in 70% of
children before bone marrow transplantation (BMT), a
number perhaps not greatly different from the normal pop-
ulation. Previous reports of pediatric transplant have gener-
ally found similar low levels before HSCT [10-12]. In contrast,
Hansson et al. [13] reported insufﬁciency in only 30% of a
population of 123 Swedish children, perhaps reﬂecting bet-
ter population vitamin D status in Sweden.
A previous study of 53 adult patients reported a signiﬁ-
cant association between low levels of 25(OH) vitamin D
before BMT and subsequent risk of chronic GVHD [14]. We
did not ﬁnd an association in our study, in agreement with
the report of Hansson et al. These differing ﬁndings mayreﬂect biological differences between children and adults or
perhaps lower frequency of chronic GVHD in pediatric pop-
ulations, limiting power to detect a modest effect.
Our data indicate reduced survival in children who were
deﬁcient in vitamin D at day 100 post-HSCT. Although most
studies addressing vitamin D deﬁciency and HSCT do not
report impact on survival, Hansson et al. [13] did report
improved survival in children with malignancies who were
vitamin D sufﬁcient compared with those who were vitamin
D insufﬁcient. Previous work has suggested an association
between acute GVHD and vitamin D insufﬁciency, perhaps
indicating an association between the steroids used to treat
GVHD and vitamin D insufﬁciency rather than a causative
role for vitamin D deﬁciency and GVHD. Sproat et al. [15]
reported that 89% of 58 adults, mostly tested because of
the presence of GVHD, were vitamin D insufﬁcient. In our
own study, we found that the frequencies of grades II to IV
and III to IV acute GVHD were not signiﬁcantly higher in
vitamin Dedeﬁcient children. However, adjustment of sur-
vival for occurrence of acute GVHD reduced the signiﬁcance
of the survival difference seen in vitamin Dedeﬁcient chil-
dren, suggesting that at least part of the increased mortality
might be due to the occurrence of GVHD and the associated
steroid use contributed to the vitamin D insufﬁciency. We
recognize that our data do not prove a causal or noncausal
relationship between vitamin D insufﬁciency and increased
mortality, and other explanations are also possible. Vitamin
D insufﬁciency has been linked with pulmonary disease such
as chronic obstructive pulmonary disease and acute respi-
ratory distress syndrome, and increased susceptibility to
infection might inﬂuence survival in our children [16-18].
Our data include measurements made before BMT and at
day 100 and showed that most childrenwhowere vitamin D
insufﬁcient at the outset remained vitamin D insufﬁcient at
day 100. Moreover, more than half the children who were
vitamin D sufﬁcient before HSCT became insufﬁcient by day
100 with standard dietary supervision. These data indicate
the need for measurement of vitamin D levels in all HSCT
recipients and aggressive vitamin D replacement, with
follow-up to ensure replete levels. Impaired hepatic and
renal function post-HSCT may increase the level of vitamin
D needed for optimal health, and compliance with therapy
may not be optimal; therefore, continued surveillance is
important. Vitamin D replacement may require higher daily
dosing than the recommended daily dietary requirement
for healthy persons, a value that is controversial and may be
lower than is needed for optimal health in light of lower
population sun exposure and poor intake of vitamin D from
diet [19]. The American Academy of Pediatrics increased
the recommended daily intake of vitamin D from 200 to 400
IU/day for children and adolescents [20]. In addition, some
investigators suggest that much higher levels (75 to 100
ng/mL), selected because these are levels at which sup-
pression of parathyroid hormone has plateaued, should be
regarded as optimal, as opposed to levels > 30 ng/mL [2-4].
Higher targets, if shown to be optimal, will require much
more aggressive replacement strategies.
All transplant recipients at our center now have a level
measured at baseline and monthly thereafter until day 100.
Insufﬁcient children (<30 ng/mL) receive replacement until
replete, using 2000 IU daily for at least 6 weeks or 50,000 IU
weekly for at least 6 weeks to achieve a level > 30 mg/dL.
Children with levels less than 10 ng/mL receive 50,000 IU
weekly for at least 6 weeks. Once replete, children continue
onmaintenance therapy of 600 to 1000 IU/day. We recognize
G. Wallace et al. / Biol Blood Marrow Transplant 21 (2015) 1627e1631 1631that requirements may be higher in children on steroids and
antifungal therapy, so children with GVHD on steroids may
need maintenance dosing of 1200 to 3000 IU/day. All HSCT
recipients are evaluated 1 year after transplant by a pediatric
endocrinologist when, among other things, vitamin D status
is assessed and bone density measured if clinically indicated.ACKNOWLEDGMENTS
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